Oculis Holding AG (OCS)
Automate Your Wheel Strategy on OCS
With Tiblio's Option Bot, you can configure your own wheel strategy including OCS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OCS
- Rev/Share 0.0051
- Book/Share 1.5205
- PB 10.2276
- Debt/Equity 0.0161
- CurrentRatio 2.3714
- ROIC -1.0167
- MktCap 848047242.7908
- FreeCF/Share -1.1312
- PFCF -15.5329
- PE -7.294
- Debt/Assets 0.0098
- DivYield 0
- ROE -1.1418
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Oculis Publishes Results of 2025 Annual General Meeting
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
Read More
Oculis Publishes Results of 2025 Annual General Meeting
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT.
Read More
Oculis to Participate in Upcoming June Investor Conferences
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:
Read More
Oculis to Participate in Upcoming June Investor Conferences
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences:
Read More
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Oculis to Present at Upcoming May Investor Conferences
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
Read More
Oculis to Present at Upcoming May Investor Conferences
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
Read More
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC).
Read More
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC).
Read More
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).
Read More
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).
Read More
About Oculis Holding AG (OCS)
- IPO Date 2021-05-18
- Website https://oculis.com
- Industry Biotechnology
- CEO Riad Sherif
- Employees 49